Tedizolid | 替地唑胺 | DA-7157 | Antibiotic | AmBeed-信号通路专用抑制剂

首页 / 抑制剂/激动剂 / 抗感染 / Antibacterial / Tedizolid

特地唑胺 /Tedizolid {[allProObj[0].p_purity_real_show]}

货号：A139024 同义名： 替地唑胺 / DA-7157;Torezolid

Tedizolid is an oxazolidinone-class antibiotic used to treat for acute bacterial skin and skin structure infections, working by inhibition of protein synthesis by binding to the 50S ribosomal subunit of the bacteria.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Tedizolid 化学结构
CAS号：856866-72-3

Tedizolid 3D分子结构
CAS号：856866-72-3

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Tedizolid 纯度/质量文件产品仅供科研

货号：A139024 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

Tedizolid 生物活性

描述

Streptococcus pneumoniae (pneumococcus) remains the most common cause of community-acquired pneumonia, meningitis, bacteremia, and otitis media. The percentages of these S. pneumoniae isolates that were categorized as susceptible (penicillin-susceptible S. pneumoniae [PSSP]), intermediate, and resistant (penicillin-resistant S. pneumoniae [PRSP]) to penicillin were found to be 93.2%, 5.6%, and 1.2%, respectively. Tedizolid is a new oxazolidinone designed for improved antibacterial potency, especially against linezolid-resistant strains. It is being developed for the treatment of serious infections caused by Gram-positive bacteria, including PRSP. Agar dilution experiments demonstrated that all 28 clinical isolates of PRSP were inhibited by tedizolid at 0.25 μg/ml (MIC (minimal inhibition concentration) range, 0.125 to 0.25 μg/ml). And the MIC₉₀ was 0.25 μg/ml with tedizolid. In mice infected systemically with a lethal inoculum of PRSP, oral administration of tedizolid phosphate was potent for survival at day 7, with 50% effective dose (ED₅₀) values ranging from 3.19 to 11.53 mg/kg of body weight/day. In the PSSP pneumonia model, the ED₅₀ for survival at day 15 was 2.80 mg/kg/day for oral tedizolid phosphate. At a dose of 10 mg/kg once daily tedizolid phosphate, pneumococcal titers in the lungs at 52 h postinfection were approximately 3 orders of magnitude lower with tedizolid phosphate treatment than with no treatment. Lung histopathology showed less inflammatory cell invasion into alveolar spaces in mice treated with tedizolid phosphate than in untreated mice. These results demonstrate that tedizolid phosphate is effective in murine models of PRSP systemic infection and PSSP pneumonia^[2].

Tedizolid 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01431833	Hepatic Impairment	Phase 1	Completed	-	United States, Florida ... 展开 >> Trius Investigator Site 001 Orlando, Florida, United States, 32809 United States, Minnesota Trius Investigator Site 002 Minneapolis, Minnesota, United States, 55404 收起 <<
NCT02097043	Healthy	Phase 1	Completed	-	Korea, Republic of ... 展开 >> Seoul National University Hospital Seoul, Korea, Republic of 收起 <<
NCT00761215	Skin Diseases, Infectious ... 展开 >> Skin Diseases, Bacterial 收起 <<	Phase 2	Completed	-	United States, Alabama ... 展开 >> Trius Study Site #011 Dothan, Alabama, United States, 36301 United States, California Trius Study site #001 Chula Vista, California, United States, 91911 Trius Study Site #009 Long Beach, California, United States, 92708 Trius Study site #002 Oceanside, California, United States, 92056 Trius Study site #010 Pasadena, California, United States, 91105 Trius Study site 007 San Francisco, California, United States, 94143 Trius Study site 003 San Jose, California, United States, 95124 United States, Georgia Trius Study site 004 Columbus, Georgia, United States, 31904 Trius Study site #006 Ludowici, Georgia, United States, 31316 Trius Study site #005 Savannah, Georgia, United States, 31406 United States, Illinois Trius Study site #012 Springfield, Illinois, United States, 62701 United States, Michigan Trius study sie #008 Detroit, Michigan, United States, 48202 收起 <<

Tedizolid 参考文献

[1]McCool R, Gould IM, et al. Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA. BMC Infect Dis. 2017 Jan 7;17(1):39.

[2]Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae

Tedizolid 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.70mL

0.54mL

0.27mL

13.50mL

2.70mL

1.35mL

27.00mL

5.40mL

2.70mL

Tedizolid 技术信息

CAS号	856866-72-3
分子式	C₁₇H₁₅FN₆O₃
分子量	370.338

别名	替地唑胺 ;DA-7157;Torezolid;Torezolid. trade name Sivextro;TR 700
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Inert atmosphere,2-8°C

溶解度

DMSO: 9 mg/mL(24.3 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01431833	Hepatic Impairment	Phase 1	Completed	-	United States, Florida ... 展开 >> Trius Investigator Site 001 Orlando, Florida, United States, 32809 United States, Minnesota Trius Investigator Site 002 Minneapolis, Minnesota, United States, 55404 收起 <<
NCT02097043	Healthy	Phase 1	Completed	-	Korea, Republic of ... 展开 >> Seoul National University Hospital Seoul, Korea, Republic of 收起 <<
NCT00761215	Skin Diseases, Infectious ... 展开 >> Skin Diseases, Bacterial 收起 <<	Phase 2	Completed	-	United States, Alabama ... 展开 >> Trius Study Site #011 Dothan, Alabama, United States, 36301 United States, California Trius Study site #001 Chula Vista, California, United States, 91911 Trius Study Site #009 Long Beach, California, United States, 92708 Trius Study site #002 Oceanside, California, United States, 92056 Trius Study site #010 Pasadena, California, United States, 91105 Trius Study site 007 San Francisco, California, United States, 94143 Trius Study site 003 San Jose, California, United States, 95124 United States, Georgia Trius Study site 004 Columbus, Georgia, United States, 31904 Trius Study site #006 Ludowici, Georgia, United States, 31316 Trius Study site #005 Savannah, Georgia, United States, 31406 United States, Illinois Trius Study site #012 Springfield, Illinois, United States, 62701 United States, Michigan Trius study sie #008 Detroit, Michigan, United States, 48202 收起 <<
NCT00761215	-		Completed	-	-
NCT00671814	Healthy Subjects	Phase 1	Completed	-	United States, Wisconsin ... 展开 >> Covance Clinical Research Unit Madison, Wisconsin, United States, 53704 收起 <<
NCT01421511	-		Completed	-	-
NCT00671359	Healthy	Phase 1	Completed	-	United States, California ... 展开 >> Covance CRU San Diego, California, United States, 92123 收起 <<
NCT01156077	Bacterial Infection	Phase 1	Completed	-	-
NCT01442831	Healthy	Phase 1	Completed	-	United States, Wisconsin ... 展开 >> Trius Investigator Site 001 Madison, Wisconsin, United States, 53704 收起 <<
NCT01452828	Renal Impairment	Phase 1	Completed	-	United States, Florida ... 展开 >> Trius Investigator Site 001 Orlando, Florida, United States, 32809 United States, Minnesota Trius Investigator Site 002 Minneapolis, Minnesota, United States, 55404 收起 <<
NCT01421511	Skin and Subcutaneous Tissue B... 展开 >>acterial Infections 收起 <<	Phase 3	Completed	-	-
NCT01461460	Healthy Volunteer	Phase 1	Completed	-	United States, Texas ... 展开 >> Trius Investigator Dallas, Texas, United States, 75247 收起 <<
NCT01170221	Skin and Subcutaneous Tissue B... 展开 >>acterial Infections 收起 <<	Phase 3	Completed	-	-
NCT01496677	Healthy Subjects	Phase 1	Completed	-	United States, Florida ... 展开 >> Trius Investigator Site 001 Daytona Beach, Florida, United States, 32117 收起 <<
NCT00983255	Bacterial Infections	Phase 1	Completed	-	United States, Wisconsin ... 展开 >> Covance Clinical Research Unit Madison, Wisconsin, United States, 53704 收起 <<
NCT01577459	Healthy Subjects	Phase 1	Completed	-	United States, Kansas ... 展开 >> Trius Investigator Site 001 Overland Park, Kansas, United States, 66212 收起 <<
NCT01623401	Healthy Subjects	Phase 1	Completed	-	United States, Texas ... 展开 >> Trius Investigator Site 001 Dallas, Texas, United States, 75247 收起 <<
NCT01519778	Major Cutaneous Abscess ... 展开 >> Cellulitis Erysipelas 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Trius Investigator Site #118 Anaheim, California, United States, 92804 Trius Investigator Site #129 Buena Park, California, United States, 90620 Trius Investigator Site 103 Chula Vista, California, United States, 91911 Trius Investigator Site 105 La Mesa, California, United States, 91942 Trius Investigator Site #106 Long Beach, California, United States, 90813 Trius Investigator Site 104 Oceanside, California, United States, 92056 United States, Georgia Trius Investigator Site 101 Columbus, Georgia, United States, 31904 Trius Investigator Site 102 Savannah, Georgia, United States, 31406 United States, Nevada Trius Investigator Site 128 Las Vegas, Nevada, United States, 89109 United States, New Jersey Trius Investigator Site 115 Somers Point, New Jersey, United States, 08244 收起 <<
NCT01170221	-		Completed	-	-
NCT01539473	Healthy Volunteers	Phase 1	Completed	-	United States, Indiana ... 展开 >> Trius Investigator Site 001 Evansville, Indiana, United States, 47710 收起 <<
NCT01967225	Skin Diseases, Infectious	Phase 3	Completed	-	Japan ... 展开 >> Nagakute, Aichi, Japan, 480-1195 Nagoya, Aichi, Japan, 455-8530 Nagoya, Aichi, Japan, 457-8510 Toyoake, Aichi, Japan, 470-1192 Yoshida, Fukui, Japan, 910-1193 Kasuga, Fukuoka, Japan, 816-0864 Kitakyushu, Fukuoka, Japan, 802-0077 Miyako-gun, Fukuoka, Japan, 800-0344 Sapporo, Hokkaido, Japan, 006-8555 Sapporo, Hokkaido, Japan, 060-0061 Amagasaki, Hyogo, Japan, 660-8511 Kobe, Hyogo, Japan, 650-0017 Inashiki-gun, Ibaraki, Japan, 300-0395 Tsukuba, Ibaraki, Japan, 305-8576 Kamakura, Kanagawa, Japan, 247-8533 Sagamihara, Kanagawa, Japan, 252-0375 Yokohama, Kanagawa, Japan, 231-8682 Koshi, Kumamoto, Japan, 861-1196 Tsu, Mie, Japan, 514-1101 Sendai, Miyagi, Japan, 983-8520 Nakagami-gun, Okinawa, Japan, 901-2393 Shimajiri, Okinawa, Japan, 901-0493 Hamamatsu, Shizuoka, Japan, 430-0929 Iwata, Shizuoka, Japan, 438-8550 Numazu, Shizuoka, Japan, 410-8555 Meguro-ku, Tokyo, Japan, 152-8902 Musashimurayama, Tokyo, Japan, 208-0011 Ota-ku, Tokyo, Japan, 143-0013 Ota-ku, Tokyo, Japan, 143-8541 Ota-ku, Tokyo, Japan, 145-0065 Setagaya-ku, Tokyo, Japan, 158-8531 Shinagawa, Tokyo, Japan, 141-8625 Shinjuku-ku, Tokyo, Japan, 162-8655 Tachikawa, Tokyo, Japan, 190-0014 Yonago, Tottori, Japan, 683-8605 Shimonoseki, Yamaguchi, Japan, 750-8520 Kofu, Yamanashi, Japan, 400-8506 Fukuoka, Japan, 810-0001 Gifu, Japan, 500-8513 Kochi, Japan, 781-8555 Kumamoto, Japan, 860-0008 Nagasaki, Japan, 852-8501 Osaka, Japan, 534-0021 Shizuoka, Japan, 420-8527 Shizuoka, Japan, 424-8636 Toyama, Japan, 930-0194 收起 <<
NCT01271998	Bacterial Infection	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Trius Investigator Site 001 Hartford, Connecticut, United States, 06102 收起 <<
NCT01967225	-		Completed	-	-
NCT00876655	Healthy	Phase 1	Completed	-	United States, Texas ... 展开 >> Covance Clinical Research Unit Austin, Texas, United States, 78752 收起 <<
NCT03176134	Acute Bacterial Skin and Skin ... 展开 >>Structure Infections 收起 <<	Phase 3	Not yet recruiting	September 18, 2021	-
NCT01519778	-		Completed	-	-
NCT00666601	Healthy	Phase 1	Completed	-	United States, Florida ... 展开 >> General Clinical Research Center Gainesville, Florida, United States, 32604 收起 <<
NCT02019420	Pneumonia	Phase 3	Completed	-	-
NCT02066402	Bacterial Infections	Phase 3	Completed	-	-
NCT02477514	Skin Diseases, Bacterial	Phase 1	Completed	-	-
NCT02991131	-		Terminated(Company decision fo... 展开 >>r 18299 TERMINATION status) 收起 <<	-	Russian Federation ... 展开 >> Multiple Locations, Russian Federation Singapore Multiple Locations, Singapore 收起 <<
NCT02276482	Skin Diseases, Infectious ... 展开 >> Skin Diseases, Bacterial 收起 <<	Phase 3	Completed	-	-
NCT02066402	-		Completed	-	-
NCT03378427	Prosthetic Joint Infection	Not Applicable	Recruiting	January 15, 2020	France ... 展开 >> GHU Garches Recruiting Garches, France, 92380 Contact: Aurélien DINH, M.D. +33 (0)1 47 10 77 58 aurelien.dinh@aphp.fr Hôpital de la Croix Rousse Recruiting Lyon, France, 69004 Contact: Tristan FERRY, M.D. Ph. D. +33 (0)4 72 07 17 55 tristan.ferry@univ-lyon1.fr 收起 <<
NCT02444234	Cystic Fibrosis	Phase 4	Completed	-	United States, California ... 展开 >> University of Southern California Los Angeles, California, United States, 90089 收起 <<
NCT02750761	Gram-Positive Bacterial Infect... 展开 >>ions 收起 <<	Phase 1	Recruiting	March 23, 2019	United States, Arkansas ... 展开 >> Call for Information (Investigational Site 0124) Recruiting Little Rock, Arkansas, United States, 72202 United States, California Call for Information (Investigational Site 0109) Recruiting Los Angeles, California, United States, 90095 Call for Information (Investigational Site 0101) Recruiting Orange, California, United States, 92868 Call for Information (Investigational Site 0102) Recruiting San Diego, California, United States, 92123 United States, Colorado Call for Information (Investigational Site 0104) Recruiting Aurora, Colorado, United States, 80045 United States, Florida Call for Information (Investigational Site 0125) Recruiting Tampa, Florida, United States, 33606 United States, Kentucky Call for Information (Investigational Site 0113) Recruiting Louisville, Kentucky, United States, 40202 United States, Louisiana Call for Information (Investigational Site 0108) Recruiting Baton Rouge, Louisiana, United States, 70808 United States, Michigan Call for Information (Investigational Site 0107) Recruiting Detroit, Michigan, United States, 48201 United States, Missouri Call for Information (Investigational Site 0112) Recruiting Kansas City, Missouri, United States, 64108 Call for Information (Investigational Site 0133) Recruiting Saint Louis, Missouri, United States, 63110 United States, Texas Call for Information (Investigational Site 0129) Recruiting Fort Worth, Texas, United States, 76104 Call for Information (Investigational Site 0130) Recruiting Houston, Texas, United States, 77030 United States, Utah Call for Information (Investigational Site 0118) Recruiting Salt Lake City, Utah, United States, 84113 Colombia MDS Colombia SAS Recruiting Bogota, Colombia Contact: Liliana Ferro 57 12191093 Norway MSD Norge A/S Recruiting Drammen, Norway Contact: Katrin Moeschlin 46857813545 Ukraine MSD Ukraine LLC Recruiting Kiev, Ukraine Contact: Serhiy Mykhaylov 38 050 3107198 United Kingdom Merck Sharp & Dohme Ltd. Recruiting Hoddesdon, United Kingdom Contact: Paul Duffy 44 01992455265 收起 <<
NCT02620787	Diabetes Woun... 展开 >>d Infection Healthy Volunteers 收起 <<	Phase 1	Recruiting	December 2017	United States, Connecticut ... 展开 >> Hartford Hospital Recruiting Hartford, Connecticut, United States, 06102 Contact: David P Nicolau, PharmD 860-972-3941 david.nicolau@hhchealth.org Contact: Arlinda Carr 860-972-6724 arlinda.carr@hhchealth.org Principal Investigator: David P Nicolau, PharmD Sub-Investigator: Joseph L Kuti, PharmD Sub-Investigator: Ashley Shepard, MD Sub-Investigator: James Nugent, MD 收起 <<
NCT02342418	Obesity	Phase 4	Completed	-	-
NCT03746327	Prostheses Infection	Phase 4	Not yet recruiting	December 30, 2020	-
NCT03009045	Bone and Joint Infection	Phase 2	Recruiting	January 2019	United States, California ... 展开 >> Harbor-UCLA Medical Center Recruiting Torrance, California, United States, 90502 Los Angeles BioMedical Research Institute (LA BioMed) Recruiting Torrance, California, United States, 90502 收起 <<
NCT03217565	Gram-Positive Infections	Phase 1	Not yet recruiting	August 3, 2021	-
NCT02342418	-		Completed	-	-

特地唑胺 /Tedizolid {[allProObj[0].p_purity_real_show]}

Tedizolid 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Tedizolid 质控信息

Tedizolid 生物活性

Tedizolid 临床研究

Tedizolid 参考文献

Tedizolid 实验方案

Tedizolid 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

特地唑胺 /Tedizolid {[allProObj[0].p_purity_real_show]}

Tedizolid 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Tedizolid 质控信息

Tedizolid 生物活性

Tedizolid 临床研究

Tedizolid 参考文献

Tedizolid 实验方案

Tedizolid 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Tedizolid 纯度/质量文件产品仅供科研